Dr Reddy’s Laboratories plunges on reporting below estimates QFY12 numbers

Drug maker, Dr Reddy’s registered growth of 27.68% in fourth quarter ended March 31, 2012 net profit at Rs 211.79 crore as compared to Rs 165.87 crore for the quarter ended March 31, 2011. Total Income has increased by 49.09% to Rs 2051.18 crore January-March quarter, 2012 from Rs 1375.77 crore for the similar quarter a period ago.

The Company, for the full year ended March 31, 2012, posted marginal growth of 2.13% in its net profit of Rs 912.36 crore as compared to Rs 893.31 crore for the year ended March 31, 2011. Company’s total income stood increased by 25.76% to Rs 6821.48 crore for the fiscal year ended March 2012 from Rs 5424.01 crore in the previous fiscal.

On Consolidated basis, the Group’s net profit stood at Rs 342.70 crore for the quarter under review as compared to Rs 334.47 crore for March quarter of previous fiscal, increase of mere 2.46%. Its total income has increased by 34.20% to Rs 2638.65 crore for the quarter as compared to Rs 1966.10 crore for the fourth quarter of FY11.

The Group’s full year ended March 31, 2012 net profit stood at Rs 1426.21 crore for the year ended March 31, 2012 as compared to Rs 1104.00 crore for the year ended March 31, 2011, up by 29.18%. Its total income rose by 30.44% to Rs 9597.24 crore for the year from Rs 7357.77 crore for the previous year.

Dr Reddys Laboratories is currently trading at Rs 1653.95, down by 45.75 points or 2.69% from its previous closing of Rs 1699.70 on the BSE.

The scrip opened at Rs 1710.00 and has touched a high and low of Rs 1714.60 and Rs 1645.00 respectively. So far 74887 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 1818.00 on 20-Apr-2012 and a 52 week low of Rs 1387.00 on 22-Aug-2011.

Last one week high and low of the scrip stood at Rs 1740.95 and Rs 1645.00 respectively. The current market cap of the company is Rs 28281.82 crore.

The promoters holding in the company stood at 25.61% while Institutions and Non-Institutions held 40.85% and 16.73% respectively.

Dr Reddy’s Laboratories’ board of directors at its meeting held on May 11, 2012, have recommended a final dividend of Rs 13.75 (275%) per equity share of Rs 5 face value, for the financial year 2011-12. The dividend on equity shares, if declared by the shareholders at the ensuing Annual General Meeting, will be credited / dispatched on or after July 27, 2012.